Investing in biotech startups is a laborious business.
Venture capitalists spend months poring over data before deciding whether to back a fledgling company. They’ll scour the scientific literature for signs that the core ideas are valid. They’ll call in the founding team for interminable grillings. They may even hire outside researchers to try to replicate key experiments.